Uriel Coquis Navarrete

Uriel Coquis Navarrete


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
IBIngeborg Becker
Ingeborg Becker
HMHaydee Miranda-Ortíz
Haydee Miranda-Ortíz
Edith Araceli Fernández-FigueroaEdith Araceli Fernández-Figueroa
Edith Araceli Fernández-Figueroa
SSSokani Sanchez-Montes
Sokani Sanchez-Montes
PCPablo Coluga-Salas
Pablo Coluga-Salas
CSChristopher Rhodes Stephens
Christopher Rhodes Stephens
(1) Background: Chagas disease is the main neglected tropical disease in America. It is estimated that around 6 million people are currently infected with the parasite in Latin America, and 25 million live in endemic areas with active transmission. The disease causes an estimated economic loss of USD 24 billion dollars annually, with a loss of 75,200 working years per year of life; it is responsible for around ~12,000 deaths annually. Although Mexico is an endemic country that recorded 10,186 new cases of Chagas disease during the period of 1990–2017, few studies have evaluated the genetic diversity of genes that could be involved in the prophylaxis and/or diagnosis of the parasite. One of the possible candidates proposed as a vaccine target is the 24 kDa trypomastigote excretory–secretory protein, Tc24, whose protection is linked to the stimulation of T. cruzi-specific CD8+ immune responses. (2) Methods: The aim of the present study was to evaluate the fine-scale genetic diversity and structure of Tc24 in T. cruzi isolates from Mexico, and to compare them with other populations reported in the Americas with the aim to reconsider the potential role of Tc24 as a key candidate for the prophylaxis and improvement of the diagnosis of Chagas disease in Mexico. (3) Results: Of the 25 Mexican isolates analysed, 48% (12) were recovered from humans and 24% (6) recovered from Triatoma barberi and Triatoma dimidiata. Phylogenetic inferences revealed a polytomy in the T. cruzi clade with two defined subgroups, one formed by all sequences of the DTU I and the other formed by DTU II–VI; both subgroups had high branch support. Genetic population analysis detected a single (monomorphic) haplotype of TcI throughout the entire distribution across both Mexico and South America. This information was supported by Nei’s pairwise distances, where the sequences of TcI showed no genetic differences. (4) Conclusions: Given that both previous studies and the findings of the present work confirmed that TcI is the only genotype detected from human isolates obtained from various states of Mexico, and that there is no significant genetic variability in any of them, it is possible to propose the development of in silico strategies for the production of antigens that optimise the diagnosis of Chagas disease, such as quantitative ELISA methods that use this region of Tc24.

18 August 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HMHaydee Miranda-Ortiz
Haydee Miranda-Ortiz
Edith Araceli Fernández-FigueroaEdith Araceli Fernández-Figueroa
Edith Araceli Fernández-Figueroa
ERErika B. Ruíz-García
Erika B. Ruíz-García
AMAnallely Muñoz-Rivas
Anallely Muñoz-Rivas
AMAlejandra Méndez-Pérez
Alejandra Méndez-Pérez
IBIngeborg Becker
Ingeborg Becker
The use of saliva for the diagnosis of SARS-CoV-2 has shown to be a good alternative to nasopharyngeal swabs (NPS), since it permits self-collection, avoids the exposure of healthy persons to infected patients, reduces waiting times, eliminates the need of personal protective equipment and is non-invasive. Yet current saliva testing is still expensive due to the need of specialized tubes containing buffers to stabilize the RNA of SARS-CoV-2 and inactivate the virus. These tubes are expensive and not always accessible in sufficient quantities. We now developed an alternative saliva testing method, using TRIzol for extraction, viral inactivation, and storage of SARS-CoV-2 RNA, combined with RT-qPCR, which was comparable in its performance to NPS. Paired saliva samples and NPS were taken from 15 asymptomatic healthcare workers and one patient with SARS-CoV-2. Further 13 patients with SARS-CoV-2 were only saliva-tested. All the tests were performed according to CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel. Saliva (4 mL) was taken in sterile 50 mL tubes, 1.5 mL TRIzol were added and mixed. Our results show that 5 μL of saliva RNA extracted with TRIzol allow for an adequate detection of the virus in patients positive for SARS-CoV-2 and was equally sensitive to NPS in TRIzol. We conclude that saliva testing using TRIzol is a recommendable method for diagnosis of SARS-CoV-2 since it has several advantages over currently used saliva tests: it can be done with normal sterile tubes, does not need cold-chain handling, is stable at room temperature, is non-invasive and less costly, making it more accessible for low-income countries. Cheaper saliva testing using TRIzol is especially relevant for low-income countries to optimize diagnosis and help define quarantine durations for families, healthcare workers, schools, and other public workplaces, thus decreasing infections and mortality caused by SARS-CoV-2.

20 April 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Edith Araceli Fernández-FigueroaEdith Araceli Fernández-Figueroa
Edith Araceli Fernández-Figueroa
JFJuan C. Falcón-Martínez
Juan C. Falcón-Martínez
José Antonio García GordilloJosé Antonio García Gordillo
José Antonio García Gordillo
UNUriel Coquis Navarrete
Uriel Coquis Navarrete
MVMelissa Valdés-Reyes
Melissa Valdés-Reyes
Erika Ruiz-GarciaErika Ruiz-Garcia
Erika Ruiz-Garcia
Malnutrition and systemic inflammation significantly worsen the prognosis of oncology patients, contributing to 10–20% of cancer-related deaths. While the Carcinoembryonic Antigen (CEA) reflects tumor burden, the Prognostic Nutritional Index (PNI) captures nutritional and immune status. This study aimed to evaluate whether the combination of CEA and PNI provides superior prognostic stratification compared to either biomarker alone in patients with metastatic colorectal cancer (mCRC). This retrospective cohort study analyzed data from 512 mCRC patients at baseline and at the first response assessment (after two months of systemic treatment). Patients were stratified into four groups based on CEA (<5 or ≥5 ng/mL) and PNI (<37.52 or ≥37.52). Overall Survival (OS) and Progression-Free Survival (PFS) were analyzed using the Kaplan-Meier method and Cox regression. Our results showed that the prevalence of PNI LOW was 49.8% at diagnosis and increased to 54.4% after chemotherapy (p = 0.047). PNI and Body Mass Index (BMI) status alone were not significant predictors of OS or PFS. In contrast, CEA was a powerful indicator, with CEA HIGH consistently predicting worse OS and PFS. Crucially, the combined CEA/PNI score provided the strongest discrimination. Patients with the high-risk profile (CEA HIGH /PNI LOW ) had a significantly increased risk of death (HR 2.41, p = 0.01) and progression (HR 2.30, p < 0.01) at baseline, compared to the lowest-risk group (CEA LOW /PNI HIGH ). This elevated risk was maintained at the first assessment (HR 2.30, p < 0.01 for death and HR 6.81, p < 0.01 for progression). We conclude that PNI alone is insufficient to predict survival in mCRC patients. However, its integration with CEA creates a robust, easily obtainable biomarker that provides superior prognostic stratification by combining information on tumor burden and host systemic status.